Internal medicine

Pathology

Clinical endpoint

Placebo

Lymphoma

Rituximab

Surgery

Physical therapy

Rheumatology

Alternative medicine

Rheumatism

Clinical trial

Medicine

The Lancet Rheumatology

Rituximab appears to be an effective and safe treatment for systemic sclerosis. Although this study has some limitations, this is the first clinical trial to show efficacy of rituximab with skin sclerosis as the primary endpoint.

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial